Impact BioMedical, Inc. (IBO)
NYSE: IBO · Pharmaceutical Preparations · Houston, TX · filing with the SEC since 2021
Who runs Impact BioMedical, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedOfficers reporting now
2
of 9 people with a filing in the last fifteen months
Directors reporting now
7
10 people on the record since 2024
Officerssales are open-market, Nov 5, 2025 to Nov 5, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Macko Todd D | Chief Financial Officer | Sep 2024 | Nov 5, 2026 | 2 · $0.00 |
| Suseck Mark | Chief Operating Officer | Sep 2024 | Nov 5, 2026 | none |
Directorssales are open-market, Nov 5, 2025 to Nov 5, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Brownell Elise | director | Sep 2024 | Nov 5, 2026 | none |
| Chan Heng Fai Ambrose | director | Sep 2024 | Nov 5, 2026 | none |
| Grady Jason | director | Sep 2024 | Nov 5, 2026 | 1 · $0.00 |
| Hibbert Castel Berisford | director | Sep 2024 | Nov 5, 2026 | none |
| Keene David K | director | Sep 2024 | Nov 5, 2026 | none |
| Sims Melissa Kaye | director | Sep 2024 | Nov 5, 2026 | none |
| Zimmerman Christian Thomas | director | Sep 2024 | Nov 5, 2026 | none |
Owners of more than 10% of a classsales are open-market, Nov 5, 2025 to Nov 5, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Dss, Inc. | 10% owner | Sep 2024 | Sep 24, 2026 | 3 · $0.00 |
Earlier names on the record3, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.